Phase I results from the phase I/II study of Rezlidhia (olutasidenib), an investigational, oral, small molecule inhibitor of mutant isocitrate dehydrogenase-1, suggests that Rezlidhia, with or without azacitidine, was well-tolerated and was associated with improvements in clinical efficacy endpoints in patients with mIDH1 acute myeloid leukemia.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe